163 related articles for article (PubMed ID: 16269190)
1. Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors.
Berg KA; Harvey JA; Spampinato U; Clarke WP
Trends Pharmacol Sci; 2005 Dec; 26(12):625-30. PubMed ID: 16269190
[TBL] [Abstract][Full Text] [Related]
2. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
Aloyo VJ; Berg KA; Spampinato U; Clarke WP; Harvey JA
Pharmacol Ther; 2009 Feb; 121(2):160-73. PubMed ID: 19109993
[TBL] [Abstract][Full Text] [Related]
3. Differences in rapid desensitization of 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptor-mediated phospholipase C activation.
Berg KA; Stout BD; Maayani S; Clarke WP
J Pharmacol Exp Ther; 2001 Nov; 299(2):593-602. PubMed ID: 11602671
[TBL] [Abstract][Full Text] [Related]
4. Differences in agonist-independent and -dependent 5-hydroxytryptamine2C receptor-mediated cell division.
Westphal RS; Sanders-Bush E
Mol Pharmacol; 1996 Mar; 49(3):474-80. PubMed ID: 8643087
[TBL] [Abstract][Full Text] [Related]
5. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
Cussac D; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Martel JC; Danty N; Rauly-Lestienne I
Eur J Pharmacol; 2008 Oct; 594(1-3):32-8. PubMed ID: 18703043
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties of the Cys23Ser single nucleotide polymorphism in human 5-HT2C receptor isoforms.
Fentress HM; Grinde E; Mazurkiewicz JE; Backstrom JR; Herrick-Davis K; Sanders-Bush E
Pharmacogenomics J; 2005; 5(4):244-54. PubMed ID: 15912142
[TBL] [Abstract][Full Text] [Related]
7. Novel actions of inverse agonists on 5-HT2C receptor systems.
Berg KA; Stout BD; Cropper JD; Maayani S; Clarke WP
Mol Pharmacol; 1999 May; 55(5):863-72. PubMed ID: 10220565
[TBL] [Abstract][Full Text] [Related]
8. Inverse agonism at serotonin and cannabinoid receptors.
Aloyo VJ; Berg KA; Clarke WP; Spampinato U; Harvey JA
Prog Mol Biol Transl Sci; 2010; 91():1-40. PubMed ID: 20691957
[TBL] [Abstract][Full Text] [Related]
9. 5-HT2C receptor agonists as an innovative approach for psychiatric disorders.
Rosenzweig-Lipson S; Dunlop J; Marquis KL
Drug News Perspect; 2007 Nov; 20(9):565-71. PubMed ID: 18176661
[TBL] [Abstract][Full Text] [Related]
10. Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression.
Berg KA; Harvey JA; Spampinato U; Clarke WP
Prog Brain Res; 2008; 172():287-305. PubMed ID: 18772038
[TBL] [Abstract][Full Text] [Related]
11. Regulation of serotonin 5-HT2C receptors by chronic ligand exposure.
Devlin MG; Smith NJ; Ryan OM; Guida E; Sexton PM; Christopoulos A
Eur J Pharmacol; 2004 Sep; 498(1-3):59-69. PubMed ID: 15363976
[TBL] [Abstract][Full Text] [Related]
12. Effects of acute intra-cerebral administration of the 5-HT(2A/C) receptor ligands DOI and ketanserin on impulse control in rats.
Hadamitzky M; Koch M
Behav Brain Res; 2009 Dec; 204(1):88-92. PubMed ID: 19467270
[TBL] [Abstract][Full Text] [Related]
13. Role of the 5-HT2C receptor in improving weight-supported stepping in adult rats spinalized as neonates.
Kao T; Shumsky JS; Jacob-Vadakot S; Himes BT; Murray M; Moxon KA
Brain Res; 2006 Sep; 1112(1):159-68. PubMed ID: 16914121
[TBL] [Abstract][Full Text] [Related]
14. Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
Kenakin T
Mol Pharmacol; 2004 Jan; 65(1):2-11. PubMed ID: 14722230
[TBL] [Abstract][Full Text] [Related]
15. Roles of 5-hydroxytryptamine (5-HT) receptor subtypes in the inhibitory effects of 5-HT on C-fiber responses of spinal wide dynamic range neurons in rats.
Liu FY; Xing GG; Qu XX; Xu IS; Han JS; Wan Y
J Pharmacol Exp Ther; 2007 Jun; 321(3):1046-53. PubMed ID: 17329553
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and in vitro pharmacological evaluation of a new series of 5-HT1A 5-HT2A and 5-HT2C receptor ligands containing a norbornene nucleus.
Fiorino F; Severino B; De Angelis F; Perissutti E; Magli E; Frecentese F; Esposito A; Massarelli P; Nencini C; Viti B; Santagada V; Caliendo G
Pharmazie; 2009 Sep; 64(9):555-64. PubMed ID: 19827295
[TBL] [Abstract][Full Text] [Related]
17. Position 5.46 of the serotonin 5-HT2A receptor contributes to a species-dependent variation for the 5-HT2C agonist (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: impact on selectivity and toxicological evaluation.
Miller KJ; Wu GY; Varnes JG; Levesque P; Li J; Li D; Robl JA; Rossi KA; Wacker DA
Mol Pharmacol; 2009 Dec; 76(6):1211-9. PubMed ID: 19767451
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.
Cid J; Alonso JM; Andrés JI; Fernández J; Gil P; Iturrino L; Matesanz E; Meert TF; Megens A; Sipido VK; Trabanco AA
Bioorg Med Chem Lett; 2004 Jun; 14(11):2765-71. PubMed ID: 15125929
[TBL] [Abstract][Full Text] [Related]
19. In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist.
Leggio GM; Cathala A; Neny M; Rouge-Pont F; Drago F; Piazza PV; Spampinato U
J Neurochem; 2009 Oct; 111(2):614-23. PubMed ID: 19702657
[TBL] [Abstract][Full Text] [Related]
20. Atypical antipsychotics and inverse agonism at 5-HT2 receptors.
Sullivan LC; Clarke WP; Berg KA
Curr Pharm Des; 2015; 21(26):3732-8. PubMed ID: 26044975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]